Aptamer:toxin conjugates that specifically target prostate tumor cells

Cancer Research

Volumn 66, Issue 12, 2006, Pages 5989-5992

  Chu, Ted C ^a   Marks III, John W ^b   Lavery, Laura A ^a   Faulkner, Sarah ^a   Rosenblum, Michael G ^b   Ellington, Andrew D ^a   Levy, Matthew ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; BIOLOGICAL MARKER; DRUG CARRIER; GELONIN; N SUCCINIMIDYL 3 (2 PYRIDYLODITHIO)PROPIONATE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG CONJUGATION; DRUG POTENCY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TUMOR CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; PLANT PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33745714275     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4583     Document Type: Article

References (20)

1. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005;288:C975-81.
2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
3. Rosenblum MG, Marks JW, Cheung LH. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Cancer Chemother Pharmacol 1999;44:343-8.
4. Rosenblum MG, Cheung LH, Liu Y, Marks JW III. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003;63:3995-4002.
5. Better M, Bernhard SL, Fishwild DM, et al. Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties. J Biol Chem 1994;269:9644-50.
6. Veenendaal LM, Jin H, Ran S, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002;99:7866-71.
7. Famulok M. Oligonucleotide aptamers that recognize small molecules. Curr Opin Struct Biol 1999;9:324-9.
8. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med 2005;56:555-83.
9. Cerchia L, Duconge F, Pestourie C, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005;3:e123.
10. Morris KN, Jensen KB, Julin CM, Weil M, Gold L. High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A 1998;95:2902-7.
11. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45:1628-50.
12. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002;62:4029-33.
13. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-72.
14. Chu TC, Shieh F, Lavery LA, et al. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron 2006;21:1859-56.
15. Yan AC, Bell KM, Breeden MM, Ellington AD. Aptamers: prospects in therapeutics and biomedicine. Front Biosci 2005;10:1802-27.
16. Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002;419:90-4.
17. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-86.
18. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 2000;106:923-8.
19. Blank M, Weinschenk T, Priemer M, Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels, selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001;276:16464-8.
20. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A 2003;100:15416-21.